Morin Interacts with α-Synuclein and Retards Its Fibrillation

Shubham Kundu1, Anupam Maity1,2, Rajdip Misra1

  • 1Structural Biology and Bioinformatics Division, Indian Institute of Chemical Biology, Council of Scientific and Industrial Research, 4, Raja S.C. Mallick Road, Kolkata 700032, India.

Insights

Morin hydrate (MOR) weakly binds to alpha-synuclein, stabilizing its structure and inhibiting aggregation. This finding offers potential therapeutic strategies for Parkinson's disease by targeting protein misfolding.

Area of Science:

  • Biochemistry and Molecular Biology
  • Neuroscience
  • Pharmacology

Background:

  • Alpha-synuclein (αS) intrinsically disordered protein aggregation is central to Parkinson's disease pathogenesis.
  • Understanding αS structural dynamics and fibrillation mechanisms is crucial for developing therapeutic interventions.

Purpose of the Study:

  • To investigate the interaction between morin hydrate (MOR) and αS in aqueous solution.
  • To determine if MOR can stabilize αS structure and inhibit its aggregation.

Main Methods:

  • Utilized intrinsic tyrosine fluorescence spectroscopy to study αS-MOR complex formation and binding affinity.
  • Employed circular dichroism spectroscopy to analyze protein conformational changes.
  • Applied atomic force microscopy and Thioflavin T fluorescence assays to assess αS aggregation and fibrillation.

Main Results:

  • MOR formed a 1:1 complex with αS, exhibiting weak binding affinity (∼4.5 × 10^4 M⁻¹) at room temperature.
  • MOR stabilized αS structure, increasing α-helical content and reducing disordered regions.
  • MOR significantly retarded αS aggregation and fibrillation, as evidenced by AFM and ThT assays.

Conclusions:

  • Morin hydrate's weak but effective interaction stabilizes αS structure through hydrophobic and hydrogen bond interactions.
  • MOR inhibits key aggregation steps like hydrophobic zipping, thereby retarding amyloid fibril formation.
  • These findings suggest MOR as a potential therapeutic agent for Parkinson's disease and related neurodegenerative disorders.